Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | F13A1 | P00488 | 1/20 | 0.57 |
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | TGM1 | P22735 | 1/20 | 0.57 |
| ▸ | MCOLN3 | Q8TDD5 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 6/20 | 0.56 |
| ▸ | PKLR | P30613 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209913 | 0.88 | HSD11B1 (0.72) | HSD11B1MEN1KMT2ASMN1; SMN2RECQL | |
| SCHEMBL3214231 | 0.85 | HSD11B1 (1.00) | HSD11B1MEN1KMT2ASMN1; SMN2F13A1 | |
| SCHEMBL3213169 | 0.85 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL3215041 | 0.83 | PKM (0.65) | HSD11B1MEN1KMT2ASMN1; SMN2RECQL | |
| SCHEMBL3226058 | 0.82 | HSD11B1 (0.77) | HSD11B1MEN1KMT2ASMN1; SMN2F13A1 | |
| SCHEMBL3225922 | 0.81 | HSD11B1 (0.76) | HSD11B1MEN1KMT2AF13A1TGM2 | |
| SCHEMBL18134604 | 0.81 | MCOLN3 (0.83) | MEN1KMT2ASMN1; SMN2MCOLN3TSHR | |
| SCHEMBL23051855 | 0.81 | SMN1; SMN2 (0.71) | HSD11B1MEN1KMT2ASMN1; SMN2MCOLN3 | |
| SCHEMBL3212035 | 0.81 | CTDSP1 (0.62) | HSD11B1MEN1KMT2ASMN1; SMN2RECQL | |
| SCHEMBL3210528 | 0.81 | HSD11B1 (0.50) | HSD11B1MEN1KMT2ASMN1; SMN2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885MEN1 1354/4885KMT2A 1609/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885MEN1 1687/4885KMT2A 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.